Volume 96, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Erythema nodosum leprosum (ENL), also known as type II leprosy reaction, is a severe immune-mediated complication of multibacillary leprosy. For ENL, corticosteroids and thalidomide are the mainstays of treatment. Other immunosuppressants, such as clofazimine, cyclosporine, and azathioprine have also been used. Although most patients with ENL respond well to conventional treatments, a small number are refractory to these therapies and have severe morbidity or mortality. We report the case of a 24-year-old man with refractory ENL treated with high-dose corticosteroids for 15 months. The patient developed steroid-dependence and serious adverse effects, and died of an intracranial infection.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. World Health Organization (WHO), 2014. Global leprosy update, 2013; reducing disease burden. Wkly Epidemiol Rec 89: 389400. [Google Scholar]
  2. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, Lockwood DN, , 2006. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 74: 868879. [Google Scholar]
  3. Manandhar R, LeMaster JW, Roche PW, , 1999. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 67: 270278. [Google Scholar]
  4. World Health Organization (WHO), 1998. Expert Committee on Leprosy. Technical Report series 874. Geneva, Switzerland: WHO. [Google Scholar]
  5. Walker SL, Waters MF, Lockwood DN, , 2007. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 78: 197215. [Google Scholar]
  6. Van Veen NH, Lockwood DN, van Brakel WH, Ramirez J, Jr Richardus JH, , 2009. Interventions for erythema nodosum leprosum. Cochrane Database Syst Rev 3: CD006949. [Google Scholar]
  7. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL, , 2006. The continuing challenges of leprosy. Clin Microbiol Rev 19: 338381.[Crossref] [Google Scholar]
  8. Ramien ML, Wong A, Keystone JS, , 2011. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor Etanercept. Clin Infect Dis 52: e133e135.[Crossref] [Google Scholar]
  9. Moghadam-Kia S, Werth VP, , 2010. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 49: 239248.[Crossref] [Google Scholar]
  10. Motta ACF, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K, Foss NT, , 2012. Leprosy reactions: coinfections as a possible risk factor. Clinics 67: 11451148.[Crossref] [Google Scholar]
  11. Sugumaran DS, , 1998. Leprosy reactions: complications of steroid therapy. Int J Lepr Other Mycobact Dis 66: 1015. [Google Scholar]
  12. Walker SL, Lebas E, Doni SN, Lockwood DN, Lambert SM, , 2014. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study. PLoS Negl Trop Dis 8: e2690.[Crossref] [Google Scholar]
  13. Davis SV, Shenoi SD, Balachandran C, Pai SB, , 2002. A fatal case of erythema necroticans. Indian J Lepr 74: 145149. [Google Scholar]
  14. De Souza JN, Machado PR, Teixeira MC, Soares NM, , 2014. Recurrence of Strongyloides stercoralis infection in a patient with Hansen's disease: a case report. Lepr Rev 85: 5862. [Google Scholar]
  15. Arunthathi S, Ebenezer G, Daniel E, Sugumaran ST, , 2001. Nocardia farcinica pleuritis in a lepromatous patient with severe necrotizing reaction: an unusual presentation. Int J Lepr Other Mycobact Dis 69: 104107. [Google Scholar]
  16. Walker SL, Balagon M, Darlong J, Doni SN, Hagge DA, Halwai V, John A, Lambert SM, Maghanoy A, Nery JA, Neupane KD, Nicholls PG, Pai VV, Parajuli P, Sales AM, Sarno E, Shah M, Tsegaye D, Lockwood DN, , 2015. ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum. PLoS Negl Trop Dis 9: e0004065.[Crossref] [Google Scholar]
  17. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F, , 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13: 560578.[Crossref] [Google Scholar]
  18. Driscoll JA, Brody SL, Kollef MH, , 2007. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67: 351368.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 16 Feb 2016
  • Accepted : 15 Feb 2017
  • Published online : 27 Mar 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error